Clinical Trials

4,804 enrolled 45 charts 1 FDA

Phase 3 Active not recruiting

Breast Neoplasms

NCT04514419 2025-11-21

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

408 enrolled

Breast Neoplasms

NCT07043725 2025-09-23

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 3 Recruiting

544 enrolled

HER2-positive Breast Cancer

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast Neoplasms

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

355 enrolled

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

80 enrolled

HER2-positive Breast Cancer

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 1 FDA

Breast Neoplasms

NCT06886659 2025-07-22

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

80 enrolled

Breast Diseases, Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

62 enrolled 18 charts

Breast Neoplasms

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Approved for marketing

Phase 1 Active not recruiting

HER2-positive Breast Cancer

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT05838066 2025-05-30

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

880 enrolled

Breast Neoplasms

NCT06747338 2025-04-24

Neo-Healer

Phase 3 Recruiting

520 enrolled

Early or Locally Advanced HER2-positive Breast Cancer

NCT02091960 2025-04-04

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

103 enrolled 17 charts

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

8,381 enrolled 22 charts

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

652 enrolled 50 charts

Breast Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

369 enrolled 19 charts

BreastHead & NeckThoracic

Breast Neoplasms

NCT05785741 2025-03-05

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

1,000 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01084876 2025-02-11

Compare

475 enrolled 25 charts

Breast Neoplasms

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

18 enrolled 14 charts

Breast Neoplasms

NCT01084863 2025-01-24

Compare

Phase 1/2 Completed

143 enrolled 23 charts

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03379428 2024-12-06

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

34 enrolled

Breast Neoplasms

NCT02675231 2024-11-26

monarcHER

Phase 2 Completed

237 enrolled 25 charts